Harnessing gut-derived bioactives and AI diagnostics for the next generation of type 2 diabetes solutions
We examine the diverse functions of microbial metabolites and the current landscape of their therapeutic applications. Additionally, the review examines the current state of AI in diagnostics, with a particular focus on microbiome parameters. As a result, we propose a novel model that combines these two fields into an adaptive and personalized approach to treating patients with T2D and improving their quality of life.
Authors
- Olena Tsyryuk (ORCID: https://orcid.org/0000-0003-4863-286X)
- Iryna Kovalchuk (ORCID: https://orcid.org/0000-0003-3380-0832)
- Yurii Penchuk (ORCID: https://orcid.org/0000-0001-5646-7003)
- Yu. V. Tseyslyer (ORCID: https://orcid.org/0000-0001-7689-9620)
- Оleksandr Kovalchuk (ORCID: https://orcid.org/0000-0002-6311-3518)
- Yu. V. Shvets (ORCID: https://orcid.org/0000-0002-6829-0820)
- Oleksandr Korotkyi (ORCID: https://orcid.org/0000-0003-1147-532X)
- Volodymyr Bulda
- Olena Lazarieva
- Vladyslav Malyi
- Mariia Saifullina
Institutions
- Taras Shevchenko National University of Kyiv (UA)
- National University of Ukraine on Physical Education and Sport (UA)
- Danylo Halytsky Lviv National Medical University (UA)
Publication Details
- Journal
- Frontiers in Endocrinology
- Published
- 2025-11-03
- DOI
- https://doi.org/10.3389/fendo.2025.1699954
- Primary Topic
- Gut microbiota and health
- Type
- article
- Field-Weighted Citation Impact
- 0.00